Clinical trials: Bulky Tumors
Hodgkin Lymphoma
Radiation Free Chemotherapy for Early Hodgkin Lymphoma
The results of the present study will provide information on short-term safety and efficacy of a iPET and MTV-adapted therapeutic strategy, aimed to assess the feasibility and safety on immediate disease control of a standard…
- Trial name
- RAFTING (NCT04866654)
- Testing
- Nivolumab 10 MG/ML
- Where
- 27 sites in Italy, Poland and 1 more
- Volunteers
- 160 people
- Sponsor
- Medical University of Gdansk
Gynecologic Cancer
Laparoscopic Ultra-radical Lymph Node Debulking Using Yasargil Clamps (Yasargil-1)
Although several studies have demonstrated the overall benefits of a laparoscopic approach for pelvic and para-aortic lymphadenectomy, complications remain a challenging scenario.
- Trial name
- NCT05318170
- Testing
- Laparoscopic ultra-radical lymph node debulking
- Where
- Italy
- Volunteers
- 43 people
- Sponsor
- University of Palermo
Solid Tumors
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
The study allowed continued safety follow-up of patients who were on single agent dovitinib or dovitinib in combination with fulvestrant treatment in a Novartis-sponsored study which had met its primary endpoint and were…
- Trial name
- NCT02116803
- Testing
- dovitinib, fulvestrant
- Where
- 9 sites in United States, Austria and 5 more
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Hodgkin Lymphoma
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Limited stage Hodgkin lymphoma is a highly curable disease, but standard treatment with ABVD chemotherapy and radiation can lead to late risks of secondary cancers, lung injury, heart injury, and others.
- Trial name
- NCT02505269
- Testing
- Brentuximab Vedotin, Adriamycin, Dacarbazine
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Lung Adenocarcinoma, Bulky Tumors
Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer
The present study will explore a novel treatment strategy for unresectable lung adenocarcinoma combining a unique unconventional radiotherapy technique for high dose partial tumor irradiation (PTI) sparing the peritumoral immune…
- Conditions
- Lung Adenocarcinoma, Bulky Tumors, Unresectable Cancer
- Trial name
- NCT07423169
- Testing
- Partial Tumor Irradiation
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Karl Landsteiner University of Health Sciences
Lymphoma
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride, vincristine sulfate, and prednisone, work in…
- Trial name
- NCT01390584
- Testing
- Doxorubicin, Bleomycin, Vinblastine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Hodgkin Lymphoma
Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult…
- Trial name
- NCT07551583
- Testing
- Nivolumab, Doxorubicin Hydrochloride, Vinblastine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma, Melanoma
Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors
This is a single arm, phase I study, evaluating the feasibility, toxicity, and degree of tumor response after novel proton pencil beam scanning (PBS GRID) treatment in patients with bulky tumors that are difficult to manage.
- Trial name
- ProGRID (NCT05121545)
- Testing
- Pro-GRID
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
High-Burden Metastatic Solid Tumors
Lesion-Allocated Therapy for Multiple Metastases and Tumor-Zoned Treatment for Bulky Tumors: A Phase II Study of Iodine-125 Seed Implantation Combined With Cryoablation in High-Burden Metastatic Disease
This open-label, randomized Phase II trial evaluates whether a strategy-based, multimodal local treatment approach improves local control compared with single-modality local therapy in patients with high-burden metastatic disease…
- Trial name
- NCT07437625
- Testing
- Iodine-125 (125I) Seed Implantation (Low-Dose-Rate Brachytherapy), cryoablation, Lesion Allocation and Tumor Zoning Strategy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Li Min
Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation
GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors
Palliative radiation therapy represents 40% of the on-going radiation at the Jewish General Hospital. In a traditional palliative radiation treatment to bulky or radioresistant tumors, radiotherapy schema varies from 24 to 30 Gys…
- Trial name
- NCT02333110
- Testing
- spatially fractionated radiation therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Lymphoma, B-Cell
External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma
The purpose of the research study is to learn whether external beam radiation can be used as a safe and effective treatment for patients with bulky (≥ 5cm) sites of non-Hodgkin's lymphoma prior to treatment with 90Y-ibritumomab…
- Trial name
- NCT00271050
- Testing
- external beam radiotherapy plus 90-Y ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Cleveland Clinic
Immunotherapy Gastrict Cancer
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1 Vs oxaliplatin plus S1.
- Trial name
- NCT05699655
- Testing
- Tislelizumab, apatinib, oxaliplatin
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Fujian Cancer Hospital
Vulvar Cancer
Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy
The study aim is to verify the accuracy of SNB combined with 18F-FDG PET/CT in cN0 invasive vulvar cancer (IVC) patients currently not candidate to SNB according to standard guidelines.
- Trial name
- GroSNaPET (NCT02969278)
- Testing
- 18FDG-PET/TC, Sentinel node biopsy
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Catholic University of the Sacred Heart
Non-Small Cell Lung Cancer, NSCLC
Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer
The investigators aim to evaluate the safety of delivering a one-time single fraction of Lattice Extreme Ablative Dose (LEAD) radiotherapy followed one day later by standard-dose, conventionally fractionated concurrent…
- Trial name
- NCT01797471
- Testing
- Lattice Extreme Ablative Dose (LEAD) Radiation Therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2…
- Conditions
- Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma
- Trial name
- NCT02466971
- Testing
- Brachytherapy, Cisplatin, External Beam Radiation Therapy
- Where
- 381 sites in United States, Canada and 1 more
- Volunteers
- 450 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Neoplasms
A Phase I Study Evaluating the Safety of Stereotactic Central Ablative Radiation Therapy (SCART) for Bulky Metastatic or Recurrent Cancer
We aim to evaluate the feasibility and toxicity of testing the tolerance and immunogenic effects of high-dose SCART radiotherapy in patients with bulky metastatic or recurrent cancer in the setting of a single-arm phase I…
- Trial name
- NCT04881981
- Testing
- SCART radiation therapy
- Where
- 4 sites in United States, China
- Volunteers
- 12 people
- Sponsor
- Baptist Health, Louisville
Hodgkin Lymphoma
Proton Therapy for Hodgkin Lymphoma
The purpose of this study is to reduce the risk of radiation related side effects and complications by treating with radiation (protons or photons) that exposes less of normal organs to low dose radiation.
- Trial name
- HL01 (NCT00850200)
- Testing
- Proton Radiation Plan, Conventional Photon Radiation Plan, Intensity Modulated Radiation Plan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Bladder Cancer
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
Clinically node positive (cN+) bladder cancer carries a poor prognosis, especially in patients who are unable to receive or fail to respond to neoadjuvant chemotherapy.
- Trial name
- CIRTiN-BC (NCT04779489)
- Testing
- personalized ultrafractionated stereotactic ablative radiotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Tumor
Evaluation of Patients With Bulky GIST Using Sunitinib
The primary purpose of this study is to determine if oral (mouth) delivery prior to tumor removal in patients with gastrointestinal stromal tumor (GIST) results in tumor shrinkage allowing for successful surgery.
- Trial name
- NCT01054911
- Testing
- Sunitinib, Surgery
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Immunotherapy, SBRT
Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors
This trial will explore effectiveness and safety using the combination therapy of camrelizumab and hyperfractionated radiotherapy in patients with massive tumor including non-small cell lung cancer, soft tissue sarcoma or…
- Conditions
- Immunotherapy, SBRT, Bulky Tumor
- Trial name
- NCT04587817
- Testing
- camrelizumab+hyperfractionated radiotherapy
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital